Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Upholding the principles of informed consent in the fight against vaccine hesitancy

Iris Kulbatski, PhD
Conditions
January 14, 2021
404 Shares
Share
Tweet
Share

Experts have taken to social media to quell misinformation and address common concerns about Pfizer’s messenger RNA (mRNA) COVID-19 vaccine, performing an important public service in support of robust vaccine uptake. However, some scientific information is being oversimplified to the point that it is misleading. The public’s decision to take a vaccine whose long-term risks are unclear should be a well-informed one. Clear communication is crucial to the process of informed consent and for building public trust in the fight against vaccine hesitancy.

Take, for example, a video posted to Twitter by a bioengineer working on COVID vaccines. Presented as “Three facts about the long-term effects of the COVID vaccine,” the researcher makes a case for the long-term safety of RNA COVID-19 vaccines. mRNA carries the instructions for making proteins and is a normal part of protein production in the body. mRNA COVID-19 vaccines deliver synthetic mRNA into the body, which tells cells to make one of the COVID-19 surface proteins – which they do. The immune system then produces an immune response to this protein, preparing the body to fight the actual virus in the future.

Fact No. 3 in the Twitter video suggests that because the RNA drug Onpattro received U.S. Food and Drug Administration (FDA) approval in 2018, has a similar formulation to RNA COVID-19 vaccines and is safe long-term, RNA COVID-19 vaccines are also safe long-term.

Indeed, Onpattro – used to treat a fatal rare neurological disorder by interfering with the RNA instructions for making an abnormal protein – and Pfizer’s vaccine are similar in that they are both “RNA in a lipid nanoparticle” that affect protein production in the body.

However, the safety comparison between Onpattro and mRNA COVID-19 vaccines is oversimplified and misleading. It implies that we can rely on the Onpattro clinical trials for assurance that all “RNA in a lipid nanoparticle” technology is safe. But the long-term safety of one type of RNA technology does not mean that another is equally as safe. If that were the case, RNA vaccines would not require independent testing to the extent that they do.

The conditions of different clinical trials can vary widely, especially when the underlying medical disorder is different. Such variations include study design, criteria for selecting research participants, and outcome measures for safety and efficacy. Here’s one example of how the Onpattro trials differ from Pfizer’s COVID-19 vaccine trials: Participants in Onpattro’s trials were pre-medicated with steroids and antihistamines to minimize infusion-related reactions to treatment. Pfizer’s clinical trial participants were not because suppressing an immune reaction in a vaccine trial goes against the principles of the therapy. In fact, the exclusion criteria for Pfizer’s trial makes anyone taking steroids or other immune suppression therapy ineligible.

This difference alone is enough to question the comparison between Onpattro’s safety and RNA vaccine safety. Pre-medication with steroids and antihistamines before receiving an “RNA in a lipid nanoparticle” therapy may improve the treatment’s safety profile. In this respect, directly comparing the safety profiles of Onpattro and RNA vaccines is unreliable.

While the concept of RNA manipulation for treating or preventing disease is not new, the FDA has never before approved a commercial vaccine made from RNA. Shorter-term safety has been shown for the Pfizer vaccine but we do not yet have information about possible longer-term side effects, because we have not yet reached long-term milestones for safety testing. The estimated completion date for the current Pfizer clinical trial is January 27, 2023. Even so, it does not include specific outcome measures for safety at the 1- or 2-year time points. We cannot know about long-term effects until we reach the long-term in clinical trials designed to gather specific safety data. Inferring long-term safety from Onpattro’s clinical trials is just that – inference, not evidence.

Moreover, there remain many outstanding questions about these vaccines that require further research. For example, Canada’s National Advisory Committee on Immunization outlines a list of research priorities for COVID-19 vaccines, including those related to efficacy, safety and immunogenicity. This is not to say that people should necessarily wait to be vaccinated until long-term safety is known, but rather that scientific information be communicated fully and clearly so that the public has an opportunity to adequately weigh the risks and benefits of their decision.

Fighting misinformation and vaccine hesitancy requires a balanced and unbiased presentation of facts to uphold informed consent principles. In our efforts to present science in an easily understandable way, let’s remain mindful of the pendulum of misinformation and prevent it from swinging too far in the opposite direction.

Iris Kulbatski is a science writer. 

Image credit: Shutterstock.com

Prev

A crisis of physician intra-professional respect [PODCAST]

January 13, 2021 Kevin 0
…
Next

Why some patients refuse care

January 14, 2021 Kevin 0
…

Tagged as: COVID, Infectious Disease

Post navigation

< Previous Post
A crisis of physician intra-professional respect [PODCAST]
Next Post >
Why some patients refuse care

More by Iris Kulbatski, PhD

  • Medical errors? Sorry, not sorry.

    Iris Kulbatski, PhD
  • “We are not that great.” Gain-of-function research highlights our hubris

    Iris Kulbatski, PhD
  • The culture of silence in Canada’s medical institutions is in desperate need of reform

    Iris Kulbatski, PhD

Related Posts

  • Rethinking consent in the age of Facebook and Cambridge Analytica

    Peter F. Nichol, MD, PhD
  • The dismantling of informed consent is a disaster

    David Penner
  • Physicians fight from the social media frontlines

    Neha Pidatala, MD
  • The basics of the MMR vaccine from a pediatrician

    Roy Benaroch, MD
  • No, the HPV vaccine isn’t optional

    Chad Hayes, MD
  • A view from Canada: Defending vaccine passports

    Bryan Thomas and Colleen M. Flood

More in Conditions

  • Second chances and simple beauty in thrift stores

    Debbie Moore-Black, RN
  • Air quality alert: Reducing our carbon footprint in health care

    Shreya Aggarwal, MD
  • A teenager’s perspective: the pressing need for mental health days in schools

    Ruhi Saldanha
  • The art of pediatrics: Connecting through observation

    Alexander Rakowsky, MD
  • Epigenetics and our inheritance to future generations

    Vishruth Nagam
  • COVID-19 unleashed an ongoing crisis of delirium in hospitals

    Christina Reppas-Rindlisbacher, MD, Nathan Stall, MD, and Paula Rochon, MD
  • Most Popular

  • Past Week

    • The erosion of patient care

      Laura de la Torre, MD | Physician
    • Challenging the diagnosis: dehydration or bias?

      Sydney Lou Bonnick, MD | Physician
    • COVID-19 unleashed an ongoing crisis of delirium in hospitals

      Christina Reppas-Rindlisbacher, MD, Nathan Stall, MD, and Paula Rochon, MD | Conditions
    • A teenager’s perspective: the pressing need for mental health days in schools

      Ruhi Saldanha | Conditions
    • Utilizing AI may reduce maternal and infant mortality

      Matt Eakins, MD | Tech
    • Physician autonomy and patient interactions in corporate health care

      Michele Luckenbaugh | Conditions
  • Past 6 Months

    • Medical gaslighting: a growing challenge in today’s medical landscape

      Tami Burdick | Conditions
    • I want to be a doctor who can provide care for women: What states must I rule out for my medical education?

      Nandini Erodula | Education
    • Balancing opioid medication in chronic pain

      L. Joseph Parker, MD | Conditions
    • The erosion of patient care

      Laura de la Torre, MD | Physician
    • Reigniting after burnout: 3 physician stories

      Kim Downey, PT | Physician
    • Mourning the silent epidemic: the physician suicide crisis and suggestions for change

      Amna Shabbir, MD | Physician
  • Recent Posts

    • Utilizing AI may reduce maternal and infant mortality

      Matt Eakins, MD | Tech
    • Unraveling the complex enigma of obesity [PODCAST]

      The Podcast by KevinMD | Podcast
    • Second chances and simple beauty in thrift stores

      Debbie Moore-Black, RN | Conditions
    • How to facilitate caregiver learning and support to improve clinical care outcomes

      Kerri Milyko, PhD | Tech
    • Air quality alert: Reducing our carbon footprint in health care

      Shreya Aggarwal, MD | Conditions
    • Exploring HIV care and advocacy [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • What Percent of Kids Had Long COVID?
  • Primary Care Visits With NPs, PAs on the Rise; C. Diff in the Intensive Care Unit
  • Are Obesity Drugs for Adolescents Cost-Effective?
  • Lab Tests That Escape FDA Oversight May Come Under Agency Review
  • Fezolinetant Benefits Women Not Suited for Hormone Therapy

Meeting Coverage

  • Fezolinetant Benefits Women Not Suited for Hormone Therapy
  • Plant-Based Estrogen Improves Lipids in Postmenopausal Women
  • New Schizophrenia Treatments Are Coming: Don't Panic
  • Loneliness Needs to Be Treated Like Any Other Health Condition, Researcher Suggests
  • Stopping Medical Misinformation Requires Early Detection
  • Most Popular

  • Past Week

    • The erosion of patient care

      Laura de la Torre, MD | Physician
    • Challenging the diagnosis: dehydration or bias?

      Sydney Lou Bonnick, MD | Physician
    • COVID-19 unleashed an ongoing crisis of delirium in hospitals

      Christina Reppas-Rindlisbacher, MD, Nathan Stall, MD, and Paula Rochon, MD | Conditions
    • A teenager’s perspective: the pressing need for mental health days in schools

      Ruhi Saldanha | Conditions
    • Utilizing AI may reduce maternal and infant mortality

      Matt Eakins, MD | Tech
    • Physician autonomy and patient interactions in corporate health care

      Michele Luckenbaugh | Conditions
  • Past 6 Months

    • Medical gaslighting: a growing challenge in today’s medical landscape

      Tami Burdick | Conditions
    • I want to be a doctor who can provide care for women: What states must I rule out for my medical education?

      Nandini Erodula | Education
    • Balancing opioid medication in chronic pain

      L. Joseph Parker, MD | Conditions
    • The erosion of patient care

      Laura de la Torre, MD | Physician
    • Reigniting after burnout: 3 physician stories

      Kim Downey, PT | Physician
    • Mourning the silent epidemic: the physician suicide crisis and suggestions for change

      Amna Shabbir, MD | Physician
  • Recent Posts

    • Utilizing AI may reduce maternal and infant mortality

      Matt Eakins, MD | Tech
    • Unraveling the complex enigma of obesity [PODCAST]

      The Podcast by KevinMD | Podcast
    • Second chances and simple beauty in thrift stores

      Debbie Moore-Black, RN | Conditions
    • How to facilitate caregiver learning and support to improve clinical care outcomes

      Kerri Milyko, PhD | Tech
    • Air quality alert: Reducing our carbon footprint in health care

      Shreya Aggarwal, MD | Conditions
    • Exploring HIV care and advocacy [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Upholding the principles of informed consent in the fight against vaccine hesitancy
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...